Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Nanjing

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Not yet open

AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection

NCT07382375Aortic Aneurysm and Dissection

DrugUlinastatin

Nanjing Medical University

Not applicable

300

Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai

2027-12-31

Not yet open

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,180

Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing

2027-11-23

Not yet open

Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients

NCT07847515Obesity / Overweight

DrugTirzepatide

Nanjing First Hospital, Nanjing Medical University

Observational

Nanjing

2027-02-01

Not yet open

Intraoperative Ultrasound Assessment of Coronary Artery and Bypass Graft Blood Flow During CABG

NCT07700524Coronary Artery Disease

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Observational

190

Nanjing

2027-01-01

Not yet open

Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC)

NCT07878026Pouchitis, UC - Ulcerative Colitis

Jinling Hospital, China

Early Phase 1

Nanjing

2027-01-01

Not yet open

Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction

NCT07331220Heart Failure With Preserved Ejection Fraction

DrugGDMT

Nanjing First Hospital, Nanjing Medical University

Not applicable

310

Nanjing

2026-12-30

Not yet open

PCI With GDMT Versus GDMT Alone for Patients With Ischemic Cardiomyopathy and Reduced LVEF

NCT07349979Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease, Stable GDMT

DrugGDMT

Nanjing First Hospital, Nanjing Medical University

Not applicable

1,154

Nanjing

2026-12-30

Not yet open

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

NCT06136507Severe Hemophilia A

DrugFRSW107

Hangzhou Gensciences Biopharmaceutical Co., Ltd.

Phase 3

Chongqing, Guangzhou, Guizhou, Hangzhou, Hefei, Nanjing, Qingdao, Shenzhen

2026-12-25

Not yet open

Individualized Inspired Oxygen Fraction Titration During Lung Surgery (iOXY-LUNG)

NCT07917897Postoperative Complications

Shanghai Pulmonary Hospital, Shanghai, China

Not applicable

628

Hefei, Nanjing, Shanghai

2026-12-20

Recruiting

A Trial of Inebilizumab in Participants With Autoimmune Hepatitis

NCT07598825Autoimmune Hepatitis, AIH

DrugInebilizumab

Amgen

Phase 3

180

Hefei, Beijing, Chongqing, Fuzhou, Zhengzhou, Wuhan, Nanjing, Suzhou

2026-12-18

Not yet open

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

NCT07789015Idiopathic Inflammatory Myopathies

DrugNerandomilast

Boehringer Ingelheim

Phase 3

270

Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing

2026-12-14

Not yet open

Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma

NCT07866612Hepatocellular Carcinoma

West China Hospital

Not applicable

Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

2026-12-01

Not yet open

Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG

NCT07918781Postoperative Atrial Fibrillation, Coronary Artery Disease

China National Center for Cardiovascular Diseases

Not applicable

1,470

Beijing, Guangzhou, Zhenzhou, Changsha, Nanjing

2026-12-01

Recruiting

Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

NCT07789184Gastric Cancer, Peritoneal Metastasis

Hua Huang, MD, PhD

Phase 3

170

Beijing, Chongqing, Zhangzhou, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang

2026-12-01

Not yet open

Hearing Intervention Effects on Brain and Language Development in Children With Bilateral Mild Hearing Loss

NCT07774728Hearing Loss, Bilateral

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Not applicable

260

Foshan, Guangzhou, Jiangyin, Kunming, Liuzhou, Nanjing, Shanghai, Sichuan

2026-11-15

Not yet open

A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin

NCT07796477T2DM (Type 2 Diabetes Mellitus)

DrugsSYH2069·Tirzepatide

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2

240

Nanjing

2026-11-06

Not yet open

ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

NCT07850063Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease

Boehringer Ingelheim

Phase 3

600

Chengdu, Luoyang, Nanjing, Shanghai

2026-11-02

Not yet open

Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients

NCT07725484Heart Failure Due to Coronary Artery Disease

DrugAlpha Lipoic Acid

Shanghai Zhongshan Hospital

Phase 3

1,188

Hefei, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Nanjing, Dalian, Xi'an

2026-11-01

Not yet open

Modified Inhaled Nitric Oxide in Ventilated Patients With Acute Respiratory Failure

NCT07892001Acute Respiratory Failure (ARF), Nitric Oxide, Pneumonia

Southeast University, China

Not applicable

424

Nanjing

2026-11-01

Not yet open

CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

NCT07763938Relapsed/Refractory B-cell Malignancies

The First Affiliated Hospital with Nanjing Medical University

Phase 1

Nanjing

2026-11-01

Not yet open

D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer

NCT07912606Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-11-01

Not yet open

Open Versus Fully Endoscopic Calcaneoplasty With Achilles Tendon Insertional Reconstruction for Haglund Syndrome

NCT07887165Haglund Syndrome, Insertional Achilles Tendinopathy

Nanjing First Hospital, Nanjing Medical University

Observational

Nanjing

2026-11-01

Not yet open

Chidamide Combined With Benmelstobart, Nab-paclitaxel, and SBRT as Second-Line Treatment for Advanced BTC

NCT07890506BTC

DrugsSBRT·Benmelstobart·Chidamide·Nab-paclitaxel

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2026-11-01

Not yet open

Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes

NCT07920939Type 2 Diabetes

DrugsInsulin glargine·SHR-3167

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

450

Nanjing, Shanghai

2026-11

Not yet open

This Study Will Evaluate the Effect and Safety of 626 in Patients With CLE

NCT07900867Cutaneous Lupus Erythematosus (CLE)

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 2

140

Nanjing, Beijing

2026-11

Not yet open

A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older

NCT07908654Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection, RSV Vaccine

Guangzhou Patronus Biotech Co., Ltd.

Phase 3

25,000

Nanjing

2026-11

Not yet open

A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma

NCT07691762Hepatocellular Carcinoma

DrugsSHR-8068·Adebrelimab·Bevacizumab

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

690

Nanjing, Shanghai

2026-11

Not yet open

Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma

NCT07888621PCNSL (Primary CNS Lymphoma), Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma (SCNSL)

DrugsGlofitamab·Obinutuzumab·Oxaliplatin·Gemcitabine

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-11

Not yet open

Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs

NCT07861425Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable

Acepodia Biotech, Inc.

Phase 1

Nanjing, Shanghai

2026-11

Recruiting

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity

NCT07874633Obesity, Overweight

DrugBerobenatide

Pfizer

Phase 3

432

Hefei, Beijing, Huizhou, Zhengzhou, Nanjing, Nanchang

2026-10-28

Recruiting

A Study to Confirm Safety and Effectiveness of RADIESSE® Injectable Implant for the Correction of Moderate to Severe Nasolabial Folds

NCT07856797Nasolabial Folds

Merz North America, Inc.

Not applicable

163

Beijing, Changde, Chengdu, Gaozhou, Hangzhou, Nanjing, Xianyang, Yibin

2026-10-27

Not yet open

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

NCT07861100Cardiovascular Risk, Obesity

DrugZenagamtide

Novo Nordisk A/S

Phase 3

8,500

Beijing, Chongqing, Guangzhou, Shijiazhuang, Luoyang, Changsha, Changzhou, Nanjing

2026-10-26

Not yet open

Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma

NCT07902596Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma

The First Affiliated Hospital with Nanjing Medical University

Observational

2,000

Shijiazhuang, Lianyungang, Nanjing, Suzhou, Qingdao, Shanghai

2026-10-25

Recruiting

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT07881458Obesity, Overweight, Diabetes Mellitus, Type 2

DrugsEloralintide and tirzepatide·Tirzepatide

Eli Lilly and Company

Phase 3

1,000

Changchun, Jinan, Luoyang Shi, Nanjing, Ningbo, Shijiazhuang, Tianjin

2026-10-16

Recruiting

A Study of Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter With TRUPULSE™ Generator in Persistent Atrial Fibrillation

NCT07845682Atrial Fibrillation

Biosense Webster, Inc.

Not applicable

150

Beijing, Jinan, Nanjing, Shanghai

2026-10-14

Recruiting

Transoral Nasal Cannula Oxygen Therapy for Mouth-Breathing Patients in the Postanesthesia Care Unit

NCT07841223Postoperative Hypoxemia

Nanjing First Hospital, Nanjing Medical University

Not applicable

Nanjing

2026-10-08

Not yet open

A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With Cetuximab and mFOLFIRI Regimen as First-Line Treatment for Recurrent or Metastatic Colorectal Cancer

NCT07874438Colorectal Cancer

DrugLenvatinib

The First Affiliated Hospital with Nanjing Medical University

Not applicable

Nanjing

2026-10-08

Recruiting

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

NCT07323095Chronic Kidney Disease

DrugFebuxostat

Atom Therapeutics Co., Ltd

Phase 2

Beijing, Nanjing, Shanghai, Hangzhou

2026-10-02

Recruiting

A Multi-modal Cohort Study of Brown Adipose Tissue Based on Paired Comparisons at Room Temperature and After Cold Exposure

NCT07908719Brown Adipose Tissue, Human

Jinling Hospital, China

Observational

500

Nanjing

2026-10-01

Not yet open

AI Assistance for Detecting Active Bleeding During DSA Procedures

NCT07824739DSA, Bleeding, AI (Artificial Intelligence), Hemorrhage

Zhongda Hospital

Not applicable

1,324

Nanjing

2026-10-01

Recruiting

Effect of Non-Clamping and Sutureless Technique on Postoperative Renal Function in Robot-Assisted Partial Nephrectomy

NCT07888608Renal Neoplasms, Localized Kidney Tumors

Shao Pengfei

Not applicable

304

Nanjing

2026-10-01

Not yet open

A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy

NCT07612670Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Liver Cirrhosis

The First Affiliated Hospital with Nanjing Medical University

Observational

700

Nanjing

2026-10-01

Recruiting

Screening Elderly Adults in Rural Communities for Heart Failure Using an NT-proBNP-Guided Strategy in China (SEARCH-HF)

NCT07885488Heart Failure

Jiangsu Taizhou People's Hospital

Not applicable

2,532

Nanjing

2026-10-01

Not yet open

Electronic PHES vs Paper-based PHES for Hepatic Encephalopathy

NCT07852416Liver Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy

The First Affiliated Hospital with Nanjing Medical University

Not applicable

Nanjing, Xi’an

2026-10-01

Recruiting

Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia

NCT07874451CLL / SLL

The First Affiliated Hospital with Nanjing Medical University

Observational

300

Nanjing

2026-10

Not yet open

A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)

NCT07832201Influenza

DrugVaxigrip

Sinovac Biotech Co., Ltd

Phase 4

150

Changsha, Chengdu, Chongqing, Guangzhou, Nanjing, Wuhan

2026-10

Not yet open

SNC116 Therapy for Refractory Systemic Lupus Erythematosus

NCT07748156Systemic Lupus Erythematosus

DrugSNC116

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Early Phase 1

Nanjing

2026-10

Recruiting

Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy

NCT07803965Acute Pancreatitis

DrugSGC001

Beijing Sungen Biomedical Technology Co., Ltd

Phase 2

129

Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo

2026-09-30

Not yet open

TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)

NCT07836309Hepatocellular Carcinoma (HCC)

Zhongda Hospital

Observational

596

Nanjing

2026-09-30

Recruiting

Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial

NCT07847710Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy

DrugsGemcitabine & oxaliplatin·Famitinib·Retlirafusp alfa·Teysuno

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-09-30

Not yet open

A Clinical Study on the Synergistic Effects of Zhen-Qi-Jie-Du Granules in Palliative Care for Advanced Colorectal Cancer

NCT07854405Colorectal Cancer

Jiangsu Famous Medical Technology Co., Ltd.

Not applicable

1,540

Nanjing

2026-09-30

Recruiting

A Study to Evaluate the Effectiveness and Safety of Restylane Shaype in the Improvement of Jawline Definition

NCT07805512Jawline Definition

Galderma R&D

Not applicable

162

Beijing, Nanjing, Chengdu, Hangzhou

2026-09-28

Not yet open

Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial): Study Protocol of a Randomized Controlled Trial

NCT07377981Dexmedetomidine, Ketamine, Analgesia, Respiratory Therapy

DrugsEsketamine·Dexmedetomidine

The First Affiliated Hospital with Nanjing Medical University

Phase 4

356

Nanjing

2026-09-28

Recruiting

HMPL-A830 in Solid Tumors

NCT07718581Solid Tumor, Adult

Hutchmed

Phase 1/2

147

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Jinan, Nanjing, Taiyuan

2026-09-24

Recruiting

Heart Rate Variability Changes and Postoperative Delirium After Major Abdominal Surgery

NCT07783464Postoperative Delirium (POD), Heart Rate Variability (HRV)

The First Affiliated Hospital with Nanjing Medical University

Observational

500

Nanjing

2026-09-21

Recruiting

Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial

NCT07698366Breast Neoplasms, Early Detection of Cancer

The First Affiliated Hospital with Nanjing Medical University

Not applicable

80,000

Kunshan, Nanjing

2026-09-20

Not yet open

Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects

NCT07796191Healthy Adult Participants

Jiangsu vcare pharmaceutical technology co., LTD

Phase 1

Nanjing

2026-09-20

Recruiting

Intra-arterial Thrombolysis For Acute Ischemic Stroke With Medium Vessel Occlusion

NCT07668323Medium Vessel Occlusion, Ischemic Stroke, Acute

DrugRt-PA

The First Affiliated Hospital with Nanjing Medical University

Phase 3

372

Nanjing

2026-09-19

Recruiting

Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07871110Prostate Cancer (CRPC)

DrugsTinengotinib·Darolutamide·Enzalutamide

TransThera Sciences (Nanjing), Inc.

Phase 2

182

Fuzhou, Guangzhou, Wuhan, Nanjing, Nantong, Jinan, Chengdu, Hangzhou

2026-09-18

Recruiting

A Study of BGM0504 in Early T2DM With Obesity

NCT07743983Type 2 Diabetes (T2DM)

DrugsBGM0504·Semaglutide

BrightGene Bio-Medical Technology Co., Ltd.

Phase 3

372

Nanjing

2026-09-17

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou

2026-09-17

Recruiting

Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness

NCT07880756Skin Quality

AbbVie

Phase 3

150

Beijing, Nanjing, Hangzhou

2026-09-16

Not yet open

A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

NCT07628582Relapsed/Refractory B-cell Malignancies

The First Affiliated Hospital with Nanjing Medical University

Phase 1

Nanjing

2026-09-15

Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsImzokitug·Pumitamig·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2

160

Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Chengdu, Hangzhou

2026-09-10

Not yet open

AI-Assisted Euploid Embryo Selection for Single-Blastocyst Transfer in Women of Advanced Maternal Age

NCT07833345Female Infertility

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

500

Nanjing

2026-09-10

Not yet open

A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)

NCT07767188Lupus Nephritis

DrugObinutuzumab

Zhao Minghui

Phase 3

Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai

2026-09-10

Not yet open

A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer

NCT07782086Breast Cancer

DrugTrastuzumab deruxtecan

Shuangyue Liu

Not applicable

Hefei, Beijing, Nanjing, Xuzhou, Dalian, Shanghai, Xi’an, Chengdu

2026-09-07

Recruiting

The Effect of Remimazolam Tosylate on the Incidence of Postoperative Delirium in Older Patients Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial

NCT07908121Delirium - Postoperative

DrugPropofol

Nanjing First Hospital, Nanjing Medical University

Not applicable

600

Nanjing

2026-09-05

Not yet open

Sphere-9 PAF China Study

NCT07789925Paroxysmal Atrial Fibrillation (PAF)

Medtronic Cardiac Ablation Solutions

Not applicable

180

Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Shenyang, Tianjin

2026-09-02

Not yet open

Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL

NCT07831395Richter Syndrome

DrugsLiposomal mitoxantrone·Pirtobrutinib·Lisaftoclax·Rituximab

Institute of Hematology & Blood Diseases Hospital, China

Phase 2

Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan

2026-09-01

Not yet open

Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

NCT07803991Overweight or Obesity

DrugSYH2069

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2

360

Nanjing

2026-09-01

Recruiting

Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease

NCT07764094PCI, Drug-coated Balloon, Coronary Artery Disease

Nanjing First Hospital, Nanjing Medical University

Observational

500

Chuzhou, Tongling, Huai'an, Lianyungang, Nanjing, Xuzhou, Yixing

2026-09-01

Not yet open

Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)

NCT07824765Unresectable Hepatocellular Carcinoma

Zhongda Hospital

Observational

2,658

Nanjing

2026-09-01

Not yet open

ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular

NCT07813572Hepatocellular Carcinoma

DrugsZG005·Avastin·Sintilimab·Bevacizumab

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

600

Nanjing

2026-09

Not yet open

Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature

NCT07815626Idiopathic Short Stature (ISS)

DrugHuman Growth Hormone

Zhongshan Sansure Hygene Biomedicine Co., Ltd.

Phase 3

240

Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing

2026-09

Not yet open

ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR

NCT07799649Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

The First Affiliated Hospital with Nanjing Medical University

Observational

150

Nanjing

2026-09

Recruiting

This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.

NCT07649122Prostate Cancer

Norroy Bioscience Co., LTD

Phase 3

232

Nanjing, Wuxi

2026-08-31

Not yet open

A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07707167LA HNSCC

DrugsPucotenlimab·Becotatug Vedotin

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2026-08-31

Recruiting

A Clinical Study of FT1 in Patients With Short Bowel Syndrome

NCT07704047Short Bowel Syndrome, SBS

Chongqing Peg-Bio Biopharm Co., Ltd.

Phase 2

Nanjing

2026-08-30

Not yet open

Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma

NCT07744750DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZL

Changzhou No.2 People's Hospital

Phase 2

Nanjing

2026-08-30

Not yet open

Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

NCT07745257HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases

DrugsCulmerciclib·Anlotinib

Sun Yat-sen University

Phase 2

Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu

2026-08-28

Recruiting

Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial

NCT07576660Acute Respiratory Distress Syndrome (ARDS)

DrugDexamethasone

Southeast University, China

Phase 3

1,704

Nanjing

2026-08-27

Recruiting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

NCT07794579Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal

DrugOrforglipron

Eli Lilly and Company

Phase 3

2,001

Chengdu, Hefei, Jinan, Luoyang Shi, Nanjing, Ningbo, Qinhuangdao Shi, Tianjin

2026-08-26

Recruiting

A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

NCT07779252Moderate to Severe Glabellar Lines

DrugCorabotase

Ipsen

Phase 3

160

Guangzhou, Changsha, Nanjing, Wuxi, Jing’an, Chengdu, Hangzhou, Beijing

2026-08-25

Recruiting

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

NCT07747857Type 2 Diabetes Mellitus Combined With Overweight or Obesity

DrugTQF3250

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1

Fuzhou, Guangzhou, Langfang, Luoyang, Wuhan, Yichang, Changsha, Nanjing

2026-08-25

Recruiting

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

500

Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo

2026-08-24

Recruiting

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

NCT07214376Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases

Pulnovo Medical, Inc.

Not applicable

750

Fuzhou, Xiamen, Nanjing, Jinan

2026-08-21

Recruiting

Clinical Study of HRS-2129 for Acute Gouty Arthritis

NCT07706777Acute Gouty Arthritis

DrugHRS-2129

Shandong Suncadia Medicine Co., Ltd.

Phase 2

Guangzhou, Nanjing

2026-08-19

Recruiting

Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults

NCT07794878Nasolabial Folds

AbbVie

Phase 3

288

Beijing, Guangzhou, Shenzhen, Nanjing, Xianyang

2026-08-19

Not yet open

Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction

NCT07800819Gastric Adenocarcinoma, Adenocarcinoma of the Esophagogastric Junction

The First Affiliated Hospital with Nanjing Medical University

Observational

250

Nanjing

2026-08-15

Not yet open

A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

NCT07741617Urologic Neoplasms

DrugsIparomlimab and Tuvonralimab·Lenvatinib

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2026-08-15

Recruiting

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

NCT07663838Randomized, Open-label, Safety, Tolerability

DrugGenSci142

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

Beijing, Xinxiang, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin

2026-08-15

Recruiting

A Phase 1/2 Study of SY-12321 in Patients With ALK-positive Advanced Malignancies

NCT07810933ALK Positive Advanced Malignancies

Shouyao Holdings (Beijing) Co. LTD

Phase 1/2

330

Guangzhou, Nanjing

2026-08-12

Active, closed

A Mass Balance Study of [14C]HRS-9057 for Injection in Healthy Participants

NCT07681479Fluid Retention Due to Heart Failure

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 1

Nanjing

2026-08-11

Recruiting

SMP-656 for HER2-Positive Advanced Breast Cancer

NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)

Chengdu SciMount Pharmatech Co., Ltd.

Phase 2

Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing

2026-08-10

Recruiting

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

NCT07615101Prostate Cancer (Diagnosis)

Norroy Bioscience Co., LTD

Phase 3

365

Nanjing, Wuxi

2026-08-06

Recruiting

ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase

NCT07751536Leptomeningeal Metastasis From Lung Cancer

DrugPemetrexed

Shuanghu Yuan

Not applicable

Hefei, Nanjing

2026-08-05

Recruiting

Analgesic Effects of Retro-superior Costotransverse Ligament Space Block for Video-assisted Thoracoscopic Surgery

NCT07745881Nerve Block, Thoracoscopic Radical Resection of Lung Cancer

Nanjing First Hospital, Nanjing Medical University

Not applicable

130

Nanjing

2026-08-05

Recruiting

A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

NCT07743944Breast Cancer

AstraZeneca

Observational

2,000

Nanjing

2026-08-05

Recruiting

Bronchoscopic Airway Clearance for Improving Lung Aeration in Mechanically Ventilated Patients With Atelectasis

NCT07594379Atelectasis, Mechanical Ventilation

Southeast University, China

Not applicable

104

Nanjing

2026-08-05

Not yet open

Epidural Spinal Cord Stimulation for Respiratory Recovery in Brain Injury

NCT07766681Brain Injuries, Respiratory Failure

Zhongda Hospital

Not applicable

Beijing, Nanjing, Suzhu

2026-08-05

Recruiting

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

NCT07468851High-risk Non-muscle-invasive Bladder Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1/2

180

Beijing, Nanjing

2026-08-05

Recruiting

Gut Oxygen Therapy for Ischemic-Hypoxic Bowel Disease

NCT07621367Chronic Ischemic-Hypoxic Enteropathy

The Second Hospital of Nanjing Medical University

Not applicable

100

Nanjing

2026-08-02

Not yet open

Evaluation of NWRD09 for HPV-16 Related Cervical HSIL

NCT07712692High-grade Squamous Intraepithelial Lesion (HSIL)

DrugNWRD09

Newish Biotech (Wuxi) Co., Ltd.

Phase 2

156

Beijing, Chongqing, Lanzhou, Baoding, Zhengzhou, Nanjing, Changchun, Jinan

2026-08-01

Recruiting

68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis

NCT07914764Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma

Nanjing First Hospital, Nanjing Medical University

Observational

Nanjing

2026-08-01

Recruiting

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists

NCT07619989Obesity & Overweight

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

Nanjing

2026-08-01

Not yet open

Diagnostic Performance of a Flexible Penile Monitoring System for ED

NCT07762469Erectile Dysfunction

Bin Xu

Observational

Nanjing

2026-08-01

Not yet open

The Efficacy of CAPCT in Patients With PTCL

NCT07746245Peripheral T-Cell Lymphoma

DrugsThalidomide·Chidamide·Azacitidine·Prednisone

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-08-01

Recruiting

A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.

NCT07900516Breast Cancer

DrugsEpirubicin·Everolimus·Letrozole·Docetaxel

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-08-01

Recruiting

Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial

NCT07731828Cervical Neoplasms

DrugAdebrelimab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-08-01

Recruiting

Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients

NCT07519512Mechanical Ventilator Care

Southeast University, China

Not applicable

1,600

Nanjing

2026-08-01

Not yet open

Yanlishuang Buccal Dropping Pills for Acute Pharyngitis

NCT07761013Acute Pharyngitis

Beijing University of Chinese Medicine

Not applicable

400

Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu

2026-08-01

Recruiting

Clinical Application of a Low-Dose CBCT AI Model

NCT07845929Cerebrovascular Diseases, Lung, Liver

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Not applicable

1,380

Hefei, Wuhan, Nanjing

2026-08-01

Not yet open

A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT07753369Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia

DrugsTQB3909·Bendamustine·Lenalidomide·Rituximab

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

128

Zhengzhou, Nanjing

2026-08

Not yet open

R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma

NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma

DrugsPenpulimab·Cytarabine·Methotrexate·Rituximab

WEI XU

Not applicable

Changzhou, Huai'an, Nanjing, Wuxi, Yixing

2026-08

Not yet open

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis

NCT07765524Primary Light Chain (AL) Amyloidosis

DrugFKC289

Shenzhen Fosun Kairos Biotechnology Co., Ltd.

Phase 1/2

Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Jinan, Shanghai, Chengdu

2026-08

Not yet open

A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy

NCT07765537Primary Membranous Nephropathy

DrugFKC289

Shenzhen Fosun Kairos Biotechnology Co., Ltd.

Phase 1/2

Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu

2026-08

Not yet open

Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application

NCT07781956Non-Muscle-Invasive Bladder Cancer (NMIBC)

Nanjing First Hospital, Nanjing Medical University

Not applicable

Nanjing

2026-08

Not yet open

Diagnostic Accuracy and Safety of the Attention-Deficit/Hyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12

NCT07683156Attention-Deficit, Hyperactivity Disorder

Chongqing Jinsaixing Medical Technology Co., Ltd

Observational

570

Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Changchun, Shanghai, Chengdu

2026-07-31

Not yet open

Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL

NCT07744724DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib

DrugsPola-R-Chp·Pirtobrutinib

Changzhou No.2 People's Hospital

Phase 2

Nanjing

2026-07-31

Recruiting

Progression, Management, and Clinical Outcomes of Coronary Artery Aneurysms

NCT07764081Coronary Artery Disease, Aneurysms, Coronary Intervention

Nanjing First Hospital, Nanjing Medical University

Observational

1,000

Nanjing

2026-07-31

Not yet open

Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL

NCT07744737DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy, Pirtobrutinib

DrugsR-Chop·Pirtobrutinib

Changzhou No.2 People's Hospital

Phase 2

Nanjing

2026-07-30

Recruiting

A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

NCT07533708mCRPC or Advanced/Metastatic Solid Tumors

Shanghai Henlius Biotech

Phase 1

Nanchang, Naning, Nanjing, Shanghai, Xiamen

2026-07-30

Not yet open

A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases

NCT07731685Pain in Bone Metastases

DrugVC004

Jiangsu vcare pharmaceutical technology co., LTD

Phase 1

Nanjing

2026-07-30

Not yet open

The COMBINE-AF Trial

NCT07633509Atrial Fibrillation (AF), Atrial Fibrillation Catheter Ablation

DrugEthanol

Yunlong Wang

Not applicable

430

Beijing, Nanjing

2026-07-27

Recruiting

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

NCT07585266Gastrointestinal Stromal Neoplasms

DrugsVelzatinib·Imatinib

GlaxoSmithKline

Phase 3

800

Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Wuhan

2026-07-27

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

NCT07670884Chronic Management of Body Weight

DrugHRS9531

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

675

Zhengzhou, Nanjing

2026-07-24

Recruiting

Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis

NCT07795723Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

454

Nanjing

2026-07-20

Recruiting

ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea

NCT07767370Diarrhea Chronic, UC - Ulcerative Colitis

DrugMesalazine

The Second Hospital of Nanjing Medical University

Early Phase 1

Nanjing

2026-07-20

Active, closed

Exercise and Mindfulness Intervention for Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT07556965Cancer Patients, Chemotherapy-Induced Peripheral Neuropathy, Exercise Intervention

Nanjing Medical University

Not applicable

Nanjing

2026-07-17

Not yet open

Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

NCT07716111Gastric or Gastroesophageal Junction Adenocarcinoma

DrugsTrastuzumab Rezatecan and Retlirafusp alfa·Pertuzumab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-07-16

Recruiting

Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations

NCT07640295Metastatic Pancreatic Ductal Adenocarcinoma

Jacobio Pharmaceuticals Co., Ltd.

Phase 1/2

Beijing, Hangzhou, Changsha, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan

2026-07-16

Recruiting

Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.

NCT07904429Helicobacter Infection

DrugsKeverprazan·Minocycline·Amoxicillin

Nanjing First Hospital, Nanjing Medical University

Phase 3

612

Nanjing

2026-07-15

Recruiting

Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)

NCT07719556Mantle Cell Lymphoma (MCL)

DrugsOrelabrutinib·Obinutuzumab·Venetoclax

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Changzhou, Nanjing

2026-07-15

Recruiting

A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL

NCT07609823Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugLacutoclax

Guangzhou Lupeng Pharmaceutical Company LTD.

Phase 2

Nanjing

2026-07-14

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

NCT07664553Type 2 Diabetes Mellitus

DrugElecoglipron

AstraZeneca

Phase 3

600

Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang

2026-07-08

Not yet open

Dynamic Multimodal Delirium Warning After Cardiac Surgery

NCT07686900Postoperative Delirium, Cardiac Surgical Procedures

Southeast University, China

Observational

200

Nanjing

2026-07-06

Recruiting

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

NCT07662213Type 2 Diabetes Mellitus

DrugsElecoglipron·Semaglutide

AstraZeneca

Phase 3

1,200

Changsha, Hefei, Huai'an, Langfang, Liangyugang, Luoyang, Nanjing, Nanyang

2026-07-06

By invitation

A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B.

NCT07918456Chronic Hepatitis B

Jiangsu Chuangyuan Life Science and Technology Co., Ltd.

Phase 1

Beijing, Zhengzhou, Nanjing

2026-07-03

Recruiting

Using Single and Combined Nudge Strategies to Promote Healthier Beverage Intake Among College Students

NCT07625969Obesity, Food Selection

Nanjing Medical University

Not applicable

1,000

Nanjing

2026-07-02

Not yet open

A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy

NCT07669740Gastric Cancer (Diagnosis)

DrugsRamucirumab and paclitaxel·Sintilimab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-07-01

Active, closed

Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diquat Concentrations in Human Blood Samples

NCT07399574Diquat Poisoning

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Observational

Nanjing

2026-07-01

Not yet open

Zishen Yutai Pill for Patients With Recurrent Implantation Failure

NCT07641088Recurrent Implantation Failure

Peking University Third Hospital

Not applicable

878

Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an

2026-07-01

Recruiting

Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy

NCT07711314Prostate Cancer (Post Prostatectomy)

DrugRezvilutamide

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2026-07-01

Not yet open

Anti-Bloating Patch for Postoperative Gastric Distension After Cardiac Surgery

NCT07677423Postoperative Gastric Distension, Postoperative Gastrointestinal Dysfunction, Cardiac Surgery

Southeast University, China

Not applicable

150

Nanjing

2026-07-01

Not yet open

Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis

NCT07706998Learning

Nanjing University

Not applicable

Nanjing

2026-07-01

Not yet open

Machine Learning-Guided LIV Selection for Adolescent Idiopathic Scoliosis

NCT07723053Adolescent Idiopathic Scoliosis, Lenke Type 1 Adolescent Idiopathic Scoliosis, Lenke Type 5 Adolescent Idiopathic Scoliosis

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

300

Nanjing

2026-07-01

Not yet open

177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial

NCT07677566Prostate Cancer, Prostate Cancer Patients

DrugsLu-PSMA·Darolutamide

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 4

Nanjing

2026-07-01

Recruiting

Nudge-Based Exercise Intervention for Adolescents With Obesity

NCT07824453Pediatric Obesity

Nanjing Children's Hospital

Not applicable

140

Nanjing

2026-07-01

Recruiting

A Study of Metformin to Improve Cardiac Function After LVAD Implantation

NCT07666698Heart Failure, Left Ventricular Assist Device

DrugMetformin Hydrochloride

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2

108

Nanjing, Hangzhou, Ha’erbin, Huai'an, Zhengzhou

2026-07-01

Not yet open

Vascular Aging and Acute Kidney Injury After Cardiac Surgery

NCT07727772Acute Kidney Injury Cardiac Surgery, Postoperative Complications, Vascular Aging

Nanjing First Hospital, Nanjing Medical University

Observational

472

Nanjing

2026-07-01

Not yet open

Early Electroacupuncture for Post-TURP LUTS

NCT07736807Benign Prostatic Hyperplasia

Zhongda Hospital

Not applicable

144

Nanjing

2026-07-01

Not yet open

Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07628595Multiple Myeloma (MM)

The First Affiliated Hospital with Nanjing Medical University

Early Phase 1

Nanjing

2026-07-01

Not yet open

Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors

NCT07738679Advanced Solid Tumors

DrugTQB3454

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

127

Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou

2026-07

Recruiting

Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)

NCT07719140Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)

DrugPrednisone

Peking Union Medical College Hospital

Phase 4

198

Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Changchun, Shanghai

2026-07

Not yet open

Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome

NCT07688161Diarrhea-predominant Irritable Bowel Syndrome

Nanjing First Hospital, Nanjing Medical University

Phase 3

106

Nanjing

2026-07

Not yet open

PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer

NCT07690878Bladder Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2026-07

Not yet open

RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases

NCT07674147Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies

The Children's Hospital of Zhejiang University School of Medicine

Early Phase 1

Nanjing, Hangzhou

2026-07

Active, closed

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

NCT07662122Obesity, Overweight

DrugBI 3034701

Boehringer Ingelheim

Phase 2

344

Huzhou, Jinan, Luoyang, Nanjing, Ningbo, Qinhuangdao, Tianjin, Yichang

2026-06-30

Recruiting

Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus

NCT07712445Arterial Thrombosis

The First Affiliated Hospital with Nanjing Medical University

Observational

Nanjing

2026-06-30

Recruiting

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

NCT07555938Multiple Myeloma

DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide

Hoffmann-La Roche

Phase 3

380

Guangzhou, Nanjing, Qingdao, Tianjin, Kunming, Hangzhou, Jinan, Nanning

2026-06-23

By invitation

Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy（PRECAL）

NCT07721441Ulcerative Colitis (UC)

Tang-Du Hospital

Observational

200

Beijing, Chongqing, Shenzhen, Wuhan, Nanjing, Shengyang, Qingdao, Xi’an

2026-06-18

Recruiting

Immune Mechanisms and ECMO Strategies for Moderate-to-Severe ARDS

NCT07726940Acute Respiratory Distress Syndrome (ARDS)

Southeast University, China

Observational

1,776

Beijing, Fuzhou, Nanjing, Jinan, Chengdu, Hangzhou, Changchun, Chenzhou

2026-06-16

Recruiting

CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

NCT07615348Metastatic Clear Cell Renal Cell Carcinoma

DrugVegfr-Tki

Jinling Hospital, China

Phase 2

Nanjing, Wuxi

2026-06-16

Not yet open

Health Behavior Intervention for Colorectal Cancer Patients

NCT07632313Colorectal Cancer

Nanjing Medical University

Not applicable

Nanjing

2026-06-15

Not yet open

Gastric Feeding for the Prevention of Stroke-Associated Pneumonia

NCT07630090Stroke

Jinling Hospital, China

Phase 4

174

Nanjing

2026-06-15

Not yet open

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

NCT07647133Chronic Kidney Disease

DrugSAL0140

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 2

249

Shenzhen, Nanjing

2026-06-15

Recruiting

Effectiveness and Safety of the Ulthera® System for Skin Laxity in the Lower Face, Submentum and Neck

NCT07614997Cutis Laxa

Merz North America, Inc.

Not applicable

218

Beijing, Guangzhou, Nanjing, Xi'an, Shanghai

2026-06-15

Not yet open

A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance

NCT07622550Metastatic Colorectal Cancer (CRC)

DrugsXelox·Fruquintinib·Serplulimab

Jiangsu Cancer Institute & Hospital

Phase 2

Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou

2026-06-15

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing

2026-06-11

Recruiting

TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

NCT07246304Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy

DrugsFludarabine·Cyclophosphamide

TCRCure Biopharma Ltd.

Early Phase 1

Nanjing

2026-06-10

Recruiting

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

NCT07517042Obesity, Weight Control

DrugMazdutide

Shanghai Zhongshan Hospital

Not applicable

420

Chongqing, Fuzhou, Xiamen, Wuhan, Nanjing, Suzhou, Shanghai, Luzhou

2026-06-10

Not yet open

Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

NCT07682415CLL / SLL

DrugSonrotoclax

Yi Shuhua

Phase 2

Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin

2026-06-08

Recruiting

A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.

NCT07622836TNBC, Adjuvant Therapy, Lymph Node Positive

The First Affiliated Hospital with Nanjing Medical University

Not applicable

Nanjing

2026-06-05

Recruiting

An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer

NCT07589569Pancreatic Cancer

DrugHRS-7058

Shandong Suncadia Medicine Co., Ltd.

Phase 2

Nanjing, Tianjin

2026-06-04

Recruiting

A Phase I Study of JSKN021 in Advanced Solid Tumors

NCT07617727Advanced Malignant Solid Tumors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1

199

Fuzhou, Nanning, Harbin, Wuhan, Nanjing, Xuzhou, Jining, Shanghai

2026-06-02

Recruiting

The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment

NCT07650318Type 2 Diabetes Mellitus (T2DM), Mild Cognitive Impairment (MCI)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

Nanjing

2026-06-01

Not yet open

Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL

NCT07643805DLBCL

DrugMevrometostat

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2

Nanjing

2026-06-01

By invitation

Effect of Liposomal Bupivacaine and Bupivacaine Hydrochloride for Superior Trunk Block of the Interscalene Brachial Plexus on Postoperative Diaphragmatic Function and Analgesia

NCT07587203Proximal Humerus Surgery, Rotator Cuff Surgery, Shoulder Arthroplasty, Shoulder Arthroscopy

DrugsBupivacaine Hydrochloride·Liposomal bupivacaine

Nanjing First Hospital, Nanjing Medical University

Not applicable

184

Nanjing, Suzhou

2026-06-01

Recruiting

Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

NCT07608978Diffuse Large B-Cell Lymphoma (DLBCL)

DrugsPola-R-Chp·Zanubrutinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-06-01

Recruiting

A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients

NCT07671378CLL (Chronic Lymphocytic Leukemia)

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-06-01

Not yet open

Intranasal Dexmedetomidine or Esketamine for Negative Postoperative Behavioral Changes in Children

NCT07570160Behavior Problem

DrugsEsketamine·Dexmedetomidine

Nanjing Children's Hospital

Phase 4

342

Nanjing

2026-06-01

Not yet open

Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis

NCT07642544Psoriasis, Psoriasis (PsO)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Observational

120

Nanjing

2026-06-01

Not yet open

STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism

NCT07603700Pulmonary Embolism, Venous Thromboembolism

DrugsUrokinase·Rt-PA·Dabigatran·Heparin

Nanjing First Hospital, Nanjing Medical University

Observational

1,300

Nanjing

2026-06-01

Active, closed

The Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury

NCT07602465Acute Kidney Injury (AKI)

Zhongda Hospital

Observational

5,000

Nanjing

2026-06-01

Recruiting

Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma

NCT07611825Advanced RCC

DrugsIpilimumab·Toripalimab

Jinling Hospital, China

Phase 2

Nanjing

2026-06-01

Recruiting

Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

NCT07672860Kidney Cancer

DrugUDCA

Jinling Hospital, China

Phase 2

162

Nanjing

2026-06-01

Recruiting

Epidural Spinal Cord Stimulation for Respiratory Recovery in Cervical SCI

NCT07722130Spinal Cord Injury Cervical, Respiratory Failure

Zhongda Hospital

Not applicable

Nanjing

2026-06-01

Recruiting

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis

R1 Therapeutics

Phase 2

168

Beijing, Zhengzhou, Nanjing, Shanghai, Chengdu

2026-06-01

Active, closed

AI-CCTA for Predicting Cardiovascular Events in CAD

NCT07832175Coronary Artery Disease, Atherosclerotic Cardiovascular Disease

Nanjing First Hospital, Nanjing Medical University

Observational

3,000

Nanjing

2026-06-01

Recruiting

Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

NCT07663253Multiple Myeloma

DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide

Shanghai Zhongshan Hospital

Observational

333

Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing

2026-06

Recruiting

Undergraduate Nursing Intern Cohort Study

NCT07682493Occupational Disidentification

Nanjing Medical University

Observational

500

Nanjing

2026-06

Not yet open

Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

NCT07627464Renal Cell Carcinoma (RCC)

DrugsAnlotinib hydrochloride·Benmelstobart

Tianjin Medical University Cancer Institute and Hospital

Phase 2

144

Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao

2026-05-31

Not yet open

Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery

NCT07594509Cardio Vascular Disease, Cardiopulmonary Bypass

DrugVericiguat

Nanjing Medical University

Not applicable

600

Nanjing

2026-05-31

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing

2026-05-31

Not yet open

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

NCT07446387Metastatic Colorectal Cancer (CRC)

DrugIparomlimab and Tuvonralimab

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2026-05-30

Not yet open

Efficacy and Safety of Transcranial Temporal Interference Stimulation for Depression

NCT07612501Major Depressive Disorder (MDD)

Yonggui Yuan

Not applicable

Nanjing

2026-05-30

Not yet open

JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

NCT07582822Advanced Solid Tumor

Biotech Pharmaceutical Co., Ltd.

Phase 1

Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu

2026-05-30

Not yet open

A Study on the Efficacy of Sodium Propionate Combined With Anti-PD-1 Immunotherapy in Gastric Cancer

NCT07615907Gastric Cancer (GC)

Jinling Hospital, China

Not applicable

Nanjing

2026-05-30

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

460

Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang, Changchun, Jinan

2026-05-27

Recruiting

Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings

NCT07620223Hepatobiliary Surgery, Prophylactic Antibiotics

DrugPiperacillin-tazobactam

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

378

Nanjing

2026-05-24

Recruiting

A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke

NCT06459427Brain Stem Hemorrhage, Robotic Surgical Procedures

Yanbing Yu

Not applicable

142

Beijing, Nanning, Shijiazhuang, Nanjing, Nantong, Nanchang, Shanghai, Tianjin

2026-05-23

Recruiting

Multicenter Validation of a Risk Prediction Model for MDRGNB Infection

NCT07603128Infection

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Observational

1,000

Nanjing, Ankang, Datong, Ganzhou, Hangzhou, Huaian, Nanning, Shanghai

2026-05-22

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

Nanjing, Shanghai, Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou

2026-05-21

Recruiting

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

NCT07616427HR+/HER2+ Early Breast Cancer

DrugsPertuzumab·Trastuzumab

Second Affiliated Hospital, Zhejiang University, School of Medicine

Phase 2

100

Nanjing, Hangzhou, Ningbo

2026-05-20

Recruiting

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

NCT07646639Rectal Cancer, Radiotherapy

DrugsAldesleukin·Folfox·Sintilimab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

122

Nanjing

2026-05-20

Recruiting

Adaptive DBS for PD

NCT07635823Parkinson Disease(PD)

Beijing Pins Medical Co., Ltd

Not applicable

Hefei, Beijing, Guangzhou, Changsha, Nanjing, Jinan, Chengdu

2026-05-16

Recruiting

FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis

NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation

Chinese Academy of Medical Sciences, Fuwai Hospital

Not applicable

300

Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan

2026-05-15

Recruiting

Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension

NCT07607275Hypertension, Essential (Primary) Hypertension

Beijing Anzhen Hospital

Phase 4

350

Beijing, Chongqing, Dalian, Hohhot, Longyan, Luohe, Nanchang, Nanjing

2026-05-15

Recruiting

The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer

NCT07596654Esophageal Carcinoma, Limited-Stage Small Cell Esophageal Carcinoma

yi shen

Observational

Nanjing

2026-05-15

Recruiting

Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07408609Gastric or Gastroesophageal Junction Adenocarcinoma

Jiangsu Cancer Institute & Hospital

Phase 2

114

Nanjing

2026-05-14

Recruiting

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

NCT07462143Colorectal (Colon or Rectal) Cancer

DrugsCapecitabine and Oxaliplatin·RC148

RemeGen Co., Ltd.

Phase 2/3

Beijing, Chongqing, Fuzhou, Meizhou, Nanjing, Shijiazhuang, Zhengzhou, Wuhan

2026-05-12

Recruiting

Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

NCT07592585Atopic Dermatitis

DrugVC005

Jiangsu vcare pharmaceutical technology co., LTD

Phase 3

360

Nanjing

2026-05-12

Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001Obesity, Heart Failure

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

5,610

Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou

2026-05-11

Active, closed

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing

2026-05-11

Recruiting

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

NCT07558850Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis

The First Affiliated Hospital with Nanjing Medical University

Not applicable

Nanjing

2026-05-10

Recruiting

Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Lifestyle Intervention

NCT07630597Obesity & Overweight

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

Nanjing

2026-05-08

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Fluorouracil·Leucovorin·Irinotecan

Mirati Therapeutics Inc.

Phase 2

170

Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan

2026-05-06

Recruiting

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

NCT07549412Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Bevacizumab

EMD Serono Research & Development Institute, Inc.

Phase 3

1,020

Beijing, Guangzhou, Meizhou, Nanning, Hong Kong, Wuhan, Nanjing, Nanchang

2026-05-06

Recruiting

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma

NCT07571551Clear Cell RCC

DrugsToripalimab·Lenvatinib

Jinling Hospital, China

Phase 2

Nanjing

2026-05-06

Recruiting

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

300

Beijing, Guangzhou, Shenzhen, Luoyang, Nanjing, Tianjin

2026-05-05

Recruiting

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

NCT07571005Obesity, Overweight, Obstructive Sleep Apnoea

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

300

Beijing, Nanjing, Suzhou, Zhenjiang, Huzhou

2026-05-05

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsDeutenzalutamide·Xofigo·FPI-2265·Cabazitaxel

AstraZeneca

Phase 3

670

Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanjing

2026-05-04

Not yet open

Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC

NCT07523789TNBC, Triple Negative Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Observational

201

Nanjing

2026-05-01

Not yet open

Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT

NCT07550894Acute Kidney Injury, Sepsis, Critically Ill Patients Requiring Continuous Renal Replacement Therapy

Sun Yat-sen University

Phase 3

220

Chongqing, Guangzhou, Nanning, Luoyang, Zhengzhou, Wuhan, Nanjing, Xi'an

2026-05-01

Not yet open

Neoadjuvant SHR-A1811 and SHR-A1701 for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

NCT07581574Gastric or Gastroesophageal Junction Adenocarcinoma

DrugTrastuzumab Rezatecan and Retlirafusp alfa

The First Affiliated Hospital with Nanjing Medical University

Phase 1

Nanjing

2026-05-01

Recruiting

Mindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment

NCT07603102Stroke, Mild Cognitive Impairment (MCI)

Nanjing Mingzhou Rehabilitation Hospital

Not applicable

Nanjing

2026-05-01

Not yet open

Prospective International Multi-center Clinical Trial of PGT-A Upgrade

NCT07533630Infertility Assisted Reproductive Technology

Reproductive & Genetic Hospital of CITIC-Xiangya

Observational

1,700

Changsha, Nanjing, Kunming

2026-05

Recruiting

A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

NCT07404553Hypercholesterolemia

DrugSHR-1918

Beijing Suncadia Pharmaceuticals Co., Ltd

Phase 2/3

126

Nanjing

2026-04-30

Not yet open

Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis

NCT07566065Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis

Chinese Academy of Medical Sciences, Fuwai Hospital

Not applicable

150

Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Jinan, Qingdao

2026-04-30

Recruiting

A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions

NCT07532538Hypopharyngeal Cancer, Laryngeal Cancer, Head and Neck Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Observational

3,000

Nanjing

2026-04-30

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

NCT07548996Type 1 Diabetes Mellitus

DrugDimethyl Fumarate Enteric

Nanjing Medical University

Phase 2/3

Nanjing

2026-04-27

Recruiting

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors

NCT07537881Solid Tumors

RemeGen Co., Ltd.

Phase 1/2

326

Hunan, Sichuan, Fujian, Guangdong, Guizhou, Heilongjiang, Changsha, Nanjing

2026-04-27

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang

2026-04-23

Recruiting

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

NCT07303777Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management

Atom Therapeutics Co., Ltd

Phase 2

200

Beijing, Dalian, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Suzhou

2026-04-23

By invitation

CHT105 for the Treatment of Refractory Lupus Nephritis

NCT07517536Systemic Lupus Erythematosus, Lupus Nephritis

DrugCHT105

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

Nanjing

2026-04-22

Recruiting

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07499232Crohn Disease

DrugsRisankizumab·Guselkumab

Janssen Research & Development, LLC

Phase 3

530

Changzhou, Chongqing, Fuzhou, Guangzhou, Nanjing, Wuhan

2026-04-21

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181Systemic Lupus Erythematosus

DrugBI 3000202

Boehringer Ingelheim

Phase 2

405

Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai

2026-04-20

Recruiting

QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer

NCT07601178TNBC, Triple Negative Breast Cancer

DrugsAnlotinib·Nab-paclitaxel

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2026-04-17

Recruiting

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China

NCT07588880Progressive Familial Intrahepatic Cholestasis

Ipsen

Observational

Beijing, Chongqing, Hunan, Nanjing, Shanghai, Xiamen

2026-04-16

Recruiting

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

NCT07496229T-cell Lymphomas

DrugsGW5282·Golidocitinib

Dizal Pharmaceuticals

Phase 1/2

220

Chongqing, Fuzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Chengdu, Taizhou

2026-04-15

Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

NCT07541521Stage IIB-III NSCLC, Sleeve Lobectomy, Robotic Surgery, Neoadjuvant Chemoimmunotherapy

Shanghai Chest Hospital

Observational

100

Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai

2026-04-13

Active, closed

A Study of SYH2082 Injection in Healthy Participants

NCT07736404Overweight or Obesity

DrugSYH2082

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 1

Nanjing

2026-04-13

Active, closed

A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents

NCT07472725Diabetes Mellitus, Type 2

DrugSHR-3167

Jiangsu HengRui Medicine Co., Ltd.

Phase 2

102

Shenzhen, Nanjing

2026-04-11

By invitation

A Post-marketing Observational Study of Oral Cholera Vaccine

NCT07300462Diarrhea

Shanghai United Cell Biotechnology Co., Ltd

Phase 4

6,000

Hefei, Beijing, Wuhan, Nanjing, Jinan

2026-04-10

Recruiting

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

NCT07479485Hepatocellular Carcinoma

DrugsMRG006A·Pucotenlimab·Bevacizumab

Lepu Biopharma Co., Ltd.

Phase 1/2

160

Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui

2026-04-08

Recruiting

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

NCT07464756Gastric Adenocarcinoma

DrugsS-1, Oxaliplatin·Retlirafusp alfa·Apatinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-04-03

Active, closed

A Study of CS060380 Tablets in Patients With MASH and Obesity

NCT07466017Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity

DrugsCS060380·Semaglutide

Cascade Pharmaceuticals, Inc

Phase 2

130

Hefei, Guangzhou, Shijiazhuang, Nanjing, Shanghai, Hangzhou, Ningbo, Wenzhou

2026-04-02

Recruiting

The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavioral Changes in Children With Autism Spectrum Disorder

NCT07324057Autism Spectrum Disorder

DrugIntranasal dexmedetomidine

Sun Fei

Not applicable

234

Nanjing

2026-04-01

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus

DrugEnpatoran

EMD Serono Research & Development Institute, Inc.

Phase 3

202

Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Baotou, Nanjing, Suzhou, Changchun

2026-04-01

Recruiting

Effects and Mechanisms of Transcranial Direct Current Stimulation Combined With Dialectical Behavior Therapy Skills Training in Adults With Attention-Deficit/Hyperactivity Disorder

NCT07565402Adult Attention Deficit Hyperactivity Disorder

Nanjing Medical University

Not applicable

Nanjing

2026-04-01

Not yet open

First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

NCT07516639Healthy Subjects (HS), SLE (Systemic Lupus)

SUNHO（China）BioPharmaceutical CO., Ltd.

Phase 1

Nanjing

2026-04-01

Not yet open

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

NCT07451665Takayasu Arteritis (TAK)

DrugsIvarmacitinib·Prednisone

Chinese SLE Treatment And Research Group

Phase 4

180

Beijing, Guanzhou, Shenzhen, Nanning, Jiaozuo, Luoyang, Wuhan, Nanjing

2026-04-01

Not yet open

Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease

NCT07317557Cerebral Small Vessel Disease, Cognitive Impairment

Jiangsu Province Nanjing Brain Hospital

Not applicable

Nanjing

2026-04-01

Recruiting

Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes

NCT07558863Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)

The First Affiliated Hospital with Nanjing Medical University

Phase 4

Nanjing

2026-04-01

Not yet open

Effect of Acupuncture on Psychoneurological Symptom Cluster in Breast Cancer Survivors

NCT07481903Psychoneurological Symptom Cluster(Pain, Insomnia, Anxiety, Fatigue, Depression, Subjective Cognitive Decline), Pain, Insomnia, Anxiety

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Not applicable

228

Beijing, Nanjing, Qingdao, Tianjin

2026-04

Active, closed

Can Perineal Post-Free Traction in Hip Arthroscopy Effectively Reduce Perineal Complications?

NCT07322705Femoroacetabular Impingement Syndrome

ChunBao Li

Not applicable

270

Beijing, Shenzhen, Luoyang, Nanjing, Xi'an, Tai’an, Shanghai, Chengdu

2026-03-30

Active, closed

A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

NCT07499050Healthy Volunteers, Overweight or Obesity

DrugRO7795081

Hoffmann-La Roche

Phase 1

Nanjing, Shanghai

2026-03-30

Recruiting

Dihydroartemisinin for MAFLD

NCT07679542MAFLD

DrugDihydroartemisinin

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2

Nanjing

2026-03-30

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

NCT07293351Advanced Renal Cell Carcinoma (RCC)

DrugsCasdatifan·Pumitamig·Cabozantinib·Yervoy

Bristol-Myers Squibb

Phase 1/2

474

Beijing, Guangzhou, Tianjin, Harbin, Changsha Shi, Nanjing, Shanghai Shi

2026-03-26

Recruiting

ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

NCT07759934Ventilator-associated Bacterial Pneumonia (VABP), Hospital-acquired Bacterial Pneumonia (HABP)

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Phase 2

Nanjing

2026-03-25

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Beijing, Chengdu, Guangzhou, Nanchang, Nanjing, Nanning, Shanghai, Sichuan

2026-03-23

Recruiting

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

NCT07293260Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

406

Beijing, Zhengzhou, Changsha, Nanjing, Yinchuan, Xi'an, Jinan

2026-03-23

Recruiting

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

NCT07353645Colorectal Cancer, Pancreatic Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2

Nanjing

2026-03-23

Recruiting

Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability

NCT07504731Acute Respiratory Distress Syndrome (ARDS)

Zhongda Hospital

Observational

Nanjing, Jinan, Chengdu

2026-03-20

Not yet open

TIS for Brain Network Modulation and Clinical Efficacy in Parkinson's Disease

NCT07480317PARKINSON DISEASE (Disorder)

Jiangsu Province Nanjing Brain Hospital

Not applicable

Nanjing

2026-03-20

Recruiting

Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension

NCT07803835Essential Hypertension, Healthy Volunteers

Shanghai Minwei Biotechnology Co., Ltd

Phase 1

Nanjing

2026-03-19

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

NCT07672561Moderate to Severe Plaque Psoriasis

DrugWD-890

Zhejiang Wenda Pharma Technology LTD.

Phase 3

375

Nanjing

2026-03-18

Recruiting

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

NCT07498478Breast Cancer

DrugsTinengotinib·Fulvestrant

TransThera Sciences (Nanjing), Inc.

Phase 2

Guangzhou, Wuhan, Changsha, Nanjing, Jinan, Linyi, Hangzhou, Beijing

2026-03-17

Recruiting

Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial

NCT07474324GC/GEJC

DrugDisitamab Vedotin

The First Affiliated Hospital with Nanjing Medical University

Phase 2

124

Nanjing

2026-03-15

Recruiting

A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease

NCT07419828Chronic Kidney Disease

DrugHRS-1780

Shandong Suncadia Medicine Co., Ltd.

Phase 3

5,386

Nanjing

2026-03-13

Recruiting

Effect of EIT-guided PEEP in ARDS Patients

NCT06990477ARDS (Acute Respiratory Distress Syndrome)

Southeast University, China

Not applicable

2,400

Hefei, Shanghai, Guangzhou, Zhengzhou, Hangzhou, Nanjing, Xuzhou, Nanchang

2026-03-13

Recruiting

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

NCT07421700Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma

DrugsPF-08634404·Enfortumab Vedotin

Pfizer

Phase 1/2

132

Beijing, Nanjing, Tianjin, Ningbo

2026-03-11

Not yet open

Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

NCT07486479Acute Myeloid Leukemia (AML)

DrugsMitoxantrone Hydrochloride Liposome·Idarubicin·Cytarabine·Azacitidine

The First Affiliated Hospital of Soochow University

Phase 3

204

Hefei, Luoyang, Wuhan, Changzhou, Huai'an, Jingjiang, Lianyungang, Nanjing

2026-03-10

Recruiting

Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases

NCT07452250Venous Diseases

DrugFerumoxytol

Min Zhou

Phase 2

Nanjing

2026-03-08

Recruiting

Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine

NCT07585370Herpes Zoster

Jiangsu Province Centers for Disease Control and Prevention

Observational

24,740

Nanjing

2026-03-06

Recruiting

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

NCT07349069Breast Cancer

DrugsTamoxifen Citrate·HRS-8080·Exemestane·Anastrozole

Shandong Suncadia Medicine Co., Ltd.

Phase 3

5,500

Nanjing, Shanghai

2026-03-04

Recruiting

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma

NCT07436949Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugBBT002

Bambusa Therapeutics

Phase 1/2

Beijing, Guangzhou, Changsha, Nanjing, Jinan, Qingdao, Yantai, Zibo

2026-03-02

Recruiting

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

NCT07528066Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC

Shanghai Chest Hospital

Observational

200

Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai

2026-03-02

Recruiting

Impact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy

NCT07452848Gallbladder Diseases, Cholelithiasis

West China Hospital

Observational

2,000

Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin

2026-03-01

Not yet open

A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)

NCT07471165Locally Advanced Perihilar Cholangiocarcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-03-01

Recruiting

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

NCT07396480Venentoclax, Myeloid Malignancies, Conditioning, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

DrugVenetoclax

First Affiliated Hospital of Zhejiang University

Phase 3

186

Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Hangzhou

2026-03-01

Not yet open

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

NCT07392866Hepatocellular Carcinoma (HCC)

DrugsSH006·Regorafenib·Capecitabine·Oxaliplatin

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2/3

120

Nanjing, Shanghai

2026-03-01

Recruiting

Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors

NCT07487597Solid Tumor

TCRCure Biopharma Ltd.

Early Phase 1

Nanjing

2026-02-28

Recruiting

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

NCT07441174Solid Tumor Cancer, PDAC

DrugsRNK08954·IN10018

InxMed (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang

2026-02-28

Recruiting

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

NCT07229638Solid Tumor

DrugSHR-9839

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1/2

Nanjing, Shanghai

2026-02-27

Active, closed

Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

NCT07308392Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 2

119

Nanjing

2026-02-25

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing

2026-02-23

Active, closed

Thymosin Alpha 1 and IgM Levels in Sepsis

NCT07922954Sepsis, Septic Shock

DrugThymalfasin

Southeast University, China

Phase 4

Nanjing

2026-02-20

Not yet open

Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX

NCT07391826Stage III Gastric Cancer

DrugsMegestrol Acetate·Serplulimab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-02-15

Recruiting

Gelaspan vs Crystalloid Therapy in Sepsis

NCT07172451Sepsis, Intra-Abdominal Infections

Shanghai Zhongshan Hospital

Phase 4

318

Guangzhou, Nanjing, Suzhou, Xuzhou, Shanghai, Chengdu, Tianjing, Hangzhou

2026-02-13

Recruiting

Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation

NCT07397234Superior Laryngeal Nerve Block

Nanjing First Hospital, Nanjing Medical University

Not applicable

Nanjing

2026-02-11

Not yet open

Intravascular Imaging-Guided Intravascular Lithotripsy for Severe Coronary Calcified Lesions.

NCT07444346Coronary Artery Calcification, Coronary Artery Disease

The First Affiliated Hospital with Nanjing Medical University

Observational

200

Nanjing

2026-02-10

Recruiting

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm

DrugsCasdatifan·PF-08634404·Axitinib·Yervoy

Pfizer

Phase 1/2

224

Beijing, Chongqing, Wuhan, Changsha, Nanjing, Jinan, Ningbo

2026-02-10

Recruiting

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

NCT07396454HER2-Negative Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-02-10

Recruiting

PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

NCT07410520Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)

DrugsOrelabrutinib·Methotrexate·Rituximab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-02-07

Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

NCT07321886Obesity, Overweight

DrugEloralintide

Eli Lilly and Company

Phase 3

1,980

Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing

2026-02-06

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

400

Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou

2026-02-04

Recruiting

Y-4 to Treat the Postherpetic Neuralgia

NCT07275762Postherpetic Neuralgia, Y-4, Pregabalin

DrugsY-4 tables·Pregabalin

Neurodawn Pharmaceutical Co., Ltd.

Phase 2

160

Nanjing

2026-02-02

Not yet open

FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma

NCT07314372Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult

DrugsCamrelizumab and apatinib·TACE·Apatinib·Camrelizumab

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2026-02-01

Not yet open

Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer

NCT07331454Gastric Cancer (GC)

The First Affiliated Hospital with Nanjing Medical University

Phase 3

335

Nanjing

2026-02-01

Not yet open

Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery

NCT07348328Cardiovascular Surgical Procedures, Major Adverse Cardiovascular Events (MACE)

Nanjing Medical University

Not applicable

1,000

Shanghai, Nanjing

2026-02-01

Recruiting

Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis

NCT07573735Atopic Dermatitis (Eczema)

DrugBlood sampling

Zhongda Hospital

Observational

Nanjing

2026-02-01

Recruiting

Safety of Robotic Surgery for GISTs at Special Anatomic Sites

NCT07405125Gastrointenstinal Stromal Tumor (GIST)

The First Affiliated Hospital with Nanjing Medical University

Not applicable

182

Nanjing

2026-02-01

Recruiting

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

NCT07418190Relapsed/Refractory Follicular Lymphoma

DrugsZanubrutinib·Lenalidomide·Tislelizumab·Rituximab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-02-01

Not yet open

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

NCT07407452Ovarian Cancers

DrugsOlaparib·Lenvatinib·Paclitaxel·Cisplatin

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2026-02-01

Not yet open

SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma

NCT07347288PTCL

DrugZeprumetostat

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-02

Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer

DrugsSigvotatug vedotin·PF-08634404

Pfizer

Phase 1/2

162

Beijing, Fuzhou, Wuhan, Nanjing, Shanghai, Taizhou

2026-01-30

Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

NCT07288177Non-small Cell Lung Cancer (NSCLC)

DrugRina-S

Genmab

Phase 2

240

Shanghai, Beijing, Changchun, Nanjing, Tianjin, Zhangjiakou, Zhengzhou

2026-01-30

Recruiting

A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer

NCT07438106Locally Advanced Pancreatic Cancer With KRAS G12D Mutation

DrugHRS-4642

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-01-28

Recruiting

A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms

NCT07228312Intracranial Aneurysm

Johnson & Johnson Medical (Shanghai) Ltd.

Observational

200

Chenzhou, Guangzhou, Nanjing, Nanyang, Taiyuan, Wuhu, Zhengzhou

2026-01-28

Recruiting

AI-Assisted Remote Insulin Pump Optimization in T1DM

NCT07732777Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

Nanjing

2026-01-28

Recruiting

Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus

NCT07258394Type 1 Diabetes

DrugDimethyl Fumarate Enteric

Nanjing Medical University

Phase 3

Nanjing

2026-01-27

Recruiting

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

NCT07281976Triple Negative Breast Cancer

DrugsLBL-024·Albumin-Bound Paclitaxel·Toripalimab

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

220

Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang

2026-01-27

Recruiting

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

NCT07318259Systemic Lupus Erythematosus

Chongqing Precision Biotech Co., Ltd

Phase 1

Nanjing

2026-01-26

Recruiting

Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy

NCT07351474Gastric Cancer, Postoperative Delirium

DrugsRemimazolam·Propofol

The First Affiliated Hospital with Nanjing Medical University

Not applicable

170

Nanjing

2026-01-21

Recruiting

Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS

NCT07362537ARDS

Southeast University, China

Not applicable

Nanjing

2026-01-20

Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

NCT07351669HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT

Zhongda Hospital

Observational

121

Nanjing

2026-01-20

Recruiting

Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

NCT07396337Acute Ischemic Stroke

Changzhou Qianhong Bio-pharma Co., Ltd.

Phase 2

320

Nanjing

2026-01-19

Recruiting

Electro-Acupuncture in Lung cancER : EALER Study

NCT07337096Non Small Cell Lung Cancer, Accupuncture, PD-1 Inhibitors

Guangzhou University of Traditional Chinese Medicine

Not applicable

424

Guangzhou, Nanjing

2026-01-15

Not yet open

Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study

NCT07311915Prostate Cancer

DrugPropranolol

Zhongda Hospital

Not applicable

Nanjing

2026-01-15

Recruiting

Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer

NCT07831993Biliary Tract Cancer

DrugsIrinotecan Hydrochloride Liposome·Fluorouracil·Leucovorin·Sintilimab

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2026-01-14

Active, closed

A Study of SYH2069 Injection in Healthy Participants

NCT07736391Overweight or Obesity, Diabetes

DrugSYH2069

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 1

104

Nanjing

2026-01-10

Recruiting

Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer

NCT07797816Biliary Tract Cancer

DrugsIrinotecan Hydrochloride Liposome·Fluorouracil·Leucovorin·Sintilimab

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2026-01-08

Recruiting

7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy

NCT07232095Helicobacter Pylori

The First Affiliated Hospital with Nanjing Medical University

Phase 4

316

Nanjing

2026-01-08

Active, closed

Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression

NCT07585877Myopia Progressing, Myopia

Zhongda Hospital

Not applicable

104

Nanjing

2026-01-05

Recruiting

Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

NCT07441993Marginal Zone Lymphoma

DrugOrelabrutinib

Institute of Hematology & Blood Diseases Hospital, China

Phase 2

Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang

2026-01-05

Not yet open

Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study )

NCT04104854Coronary Heart Disease

Nanjing First Hospital, Nanjing Medical University

Not applicable

220

Nanjing

2026-01-01

Recruiting

Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction

NCT07537296Acute Myocardial Infarction (AMI)

Nanjing First Hospital, Nanjing Medical University

Observational

1,000

Nanjing

2026-01-01

Recruiting

Intravascular Imaging-Guided Versus Angiography- Guided PCI in Patients With DES-ISR

NCT07297641PCI, In-stent Restenosis, Intravascular Imaging Device

Nanjing First Hospital, Nanjing Medical University

Observational

1,500

Nanjing

2026-01-01

Recruiting

40 Hz Flickering for Insomnia in Parkinson's Disease

NCT07323121Parkinson Disease, Insomnia

Jiangsu Province Nanjing Brain Hospital

Not applicable

Nanjing

2026-01-01

Recruiting

Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease

NCT07299240Parkinson Disease (PD), Insomnia

Jiangsu Province Nanjing Brain Hospital

Not applicable

Nanjing

2026-01-01

Recruiting

Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry-Based Observational Study

NCT07284888Acute Respiratory Distress Syndrome

Southeast University, China

Observational

1,000

Nanjing

2026-01-01

Recruiting

Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma

NCT07310173HCC - Hepatocellular Carcinoma

DrugsAST-3424·Regorafenib

Zhejiang Hisun Pharmaceutical Co. Ltd.

Phase 2

Nanjing

2026-01-01

Not yet open

A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

NCT07365371Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)

DrugAflibercept Intravitreous

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 4

174

Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City

2026-01-01

Not yet open

Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study )

NCT04119986Coronary Heart Disease

Nanjing First Hospital, Nanjing Medical University

Not applicable

220

Nanjing

2026-01-01

Not yet open

QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer

NCT07315035Gastric Cancer Stage III

DrugLenvatinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2026-01-01

Not yet open

Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS

NCT07327268ARDS (Acute Respiratory Distress Syndrome), Electrical Impedance Tomography (EIT), Pulmonary Perfusion

Southeast University, China

Observational

Nanjing

2026-01-01

Recruiting

Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial

NCT07349875Coronary Artery Disease (CAD)

DrugColchicine

Nanjing First Hospital, Nanjing Medical University

Phase 4

3,826

Nanjing

2026-01-01

Recruiting

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

NCT07311577Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent

DrugsDisitamab Vedotin·Bevacizumab·Carboplatin

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2026-01-01

Not yet open

KN5501 Cell Injection for Refractory SLE(CLEAR)

NCT07358988Systemic Lupus Erthematosus (SLE)

Ruitherapeutics Co., LTD

Phase 1

Bengbu, Beijing, Luoyang, Wuhan, Nanjing, Shanghai

2026-01

Recruiting

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

NCT07331467Systemic Lupus Erythematosus

Chongqing Precision Biotech Co., Ltd

Phase 1

Nanjing

2026-01

Not yet open

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

NCT07328919Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

138

Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang

2026-01

Recruiting

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

NCT07289763Primary Membranous Nephropathy

DrugSHR-2173

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 2

Nanjing

2025-12-31

Not yet open

Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery

NCT06728605Coronary Heart Disease (CHD), Cardio-pulmonary Bypass, Congestive Heart Failure Chronic, Cardiogenic Shock Acute

Nanjing Medical University

Not applicable

400

Nanjing

2025-12-31

Recruiting

Validation and Precision Treatment of Inflammatory Subphenotypes in Acute Respiratory Distress Syndrome: A Multicenter Cohort Study

NCT07289711Acute Respiratory Distress Syndrome

Southeast University, China

Observational

500

Nanjing

2025-12-29

Recruiting

Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

NCT07298200Advanced Gastric Cancer

DrugsTumor vaccine-induced specific T-cell·XH001

Jia Wei

Phase 1

Nanjing

2025-12-26

Recruiting

Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC

NCT07769827HBV-HCC, Unresectable Advanced HBV-related Liver Cancer

Jinling Hospital, China

Not applicable

Nanjing

2025-12-26

Active, closed

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

NCT07285902Obesity

DrugsHRS9531·Semaglutide

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

572

Beijing, Nanjing

2025-12-25

Not yet open

Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma

NCT05912582Nasopharyngeal Carcinoma

Jiangsu Cancer Institute & Hospital

Observational

Nanjing

2025-12-25

Recruiting

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

NCT07317414Hepatocellular Carcinoma

DrugsAtezolizumab·Bevacizumab

Peking Union Medical College Hospital

Phase 2

158

Beijing, Nanjing, Xuzhou

2025-12-24

Active, closed

Efficacy and Safety of a Novel ERCP Robot in the Treatment of Common Bile Duct Stone

NCT07368335ERCP, Robot Surgery, Common Bile Duct Stone

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

200

Nanjing

2025-12-24

Recruiting

Food Intake-Related Brain and Metabolic Responses in Obesity

NCT07392905Obesity, Brain Function, Metabolomics, Feeding Behavior

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

Nanjing

2025-12-21

By invitation

Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy

NCT07371247Esophageal Cancer, MRD, ctDNA

The First Affiliated Hospital with Nanjing Medical University

Early Phase 1

Nanjing

2025-12-20

Recruiting

GenSci143 in Participants With Advanced Solid Tumors

NCT07252414Advanced Solid Tumors

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

180

Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou

2025-12-20

Recruiting

A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic guidanCe for Hemorrhagic Stroke: Large Basal Ganglia Hemorrhage

NCT06484374Hematoma Brain, Large Basal Ganglia Hemorrhage

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

198

Nanjing

2025-12-20

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin

2025-12-19

Recruiting

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT07252739Malignant Neoplasm

DrugsCalderasib·Sacituzumab tirumotecan·Cetuximab·Keytruda

Merck Sharp & Dohme LLC

Phase 2

140

Nanjing, Nanchang, Shanghai, Chengdu

2025-12-19

Not yet open

Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial

NCT07286942NSCLC, NSCLC (Non-small Cell Lung Cancer)

DrugLenvatinib

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2025-12-18

Recruiting

A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects

NCT07327281Hyperglycemia

DrugTQF3250

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1

Nanjing

2025-12-18

Recruiting

Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma

NCT07277439Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-12-16

Recruiting

A Phase II Trial of LM103 in Advanced Melanoma

NCT07310784Advanced Melanoma

DrugLM103 TILs

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2

Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun

2025-12-16

Recruiting

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

NCT07260708Advanced Cancers

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 1

Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan

2025-12-16

Recruiting

A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

NCT07323173Systemic Lupus Erythematosus

Nanjing Leads Biolabs Co.,Ltd

Phase 1

117

Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan

2025-12-16

Not yet open

Multicenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound

NCT07271745Prediabetes

Chunyan Ma

Observational

1,740

Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun

2025-12-15

Recruiting

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer

DrugIparomlimab and Tuvonralimab

Peking University

Phase 2

106

Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu

2025-12-15

Active, closed

Efficacy and Safety of ZT006 in Overweight and Obese Participants

NCT07230132Overweight , Obesity

Beijing QL Biopharmaceutical Co.,Ltd

Phase 2

184

Handan, Langfang, Harbin, Luoyang, Chenzhou, Yueyang, Nanjing, Jinan

2025-12-12

Recruiting

A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+

NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury

Vantive Health LLC

Not applicable

Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu

2025-12-11

Recruiting

Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction

NCT07237542Ischemic Stroke, Remote Ischaemic Preconditioning

Jinling Hospital, China

Not applicable

910

Nanjing

2025-12-11

Recruiting

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267Breast Cancer, Advanced Solid Tumor

DrugBG-75202

BeOne Medicines

Phase 1

Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai

2025-12-11

Recruiting

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

NCT07226349Advanced Solid Tumor

DrugsBGB-43395·Fulvestrant

BeOne Medicines

Phase 1

105

Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang

2025-12-11

Recruiting

A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis

NCT07302360Colitis, Ulcerative

Xian-Janssen Pharmaceutical Ltd.

Observational

200

Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shenzhen, Shijiazhuang, Tianjin

2025-12-11

Recruiting

A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07294625Multiple Myeloma

The First Affiliated Hospital with Nanjing Medical University

Early Phase 1

Zhengzhou, Nanjing, Xuzhou, Shanghai, Xi’an

2025-12-10

Not yet open

Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer

NCT07277452Pancreatic Cancer, Adult

DrugNimotuzumab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

156

Nanjing, Beijing

2025-12-10

Recruiting

A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

NCT07179679Multiple Myeloma

DrugTQB2934

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an

2025-12-09

Recruiting

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

NCT07340463Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)

DrugsBelimumab·Mycophenolate Mofetil·Telitacicept

Nanjing University School of Medicine

Phase 2

Nanjing

2025-12-08

Active, closed

CMTS0515-auWMT for Radiation Enteritis

NCT07331688Radiation Enteritis

The Second Hospital of Nanjing Medical University

Phase 1/2

Nanjing

2025-12-08

Recruiting

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

NCT07230106Prostate Cancer

DrugsRezvilutamide·Ris-Rez·Zeprumetostat·Abiraterone

Jiangsu HengRui Medicine Co., Ltd.

Phase 2

218

Nanjing, Tianjin

2025-12-08

Not yet open

Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT07266155Paroxysmal Nocturnal Hemoglobinuria

DrugLP-005

Longbio Pharma

Phase 2

Nanjing

2025-12-05

Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

NCT07209111Neoplasm Malignant

DrugsCalderasib·Cetuximab

Merck Sharp & Dohme LLC

Phase 2

150

Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang

2025-12-04

Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer

DrugCretostimogene Grenadenorepvec

Lepu Biopharma Co., Ltd.

Phase 2

Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan

2025-12-04

Recruiting

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus

DrugSurovatamig

AstraZeneca

Phase 1

Beijing, Chengdu, Nanjing

2025-12-02

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou

2025-12-02

Not yet open

Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS

NCT07261072Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab

DrugSecukinumab

Peking Union Medical College

Phase 4

Nanjing

2025-12-01

Not yet open

Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease

NCT07268807Heart Failure, CKD, Anemia

DrugRoxadustat

Zhongda Hospital

Observational

200

Nanjing

2025-12-01

Recruiting

Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

NCT07530094Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

DrugCamrelizumab

Ning Jiang, M.D./Ph.D.

Phase 2

Nanjing

2025-12-01

Recruiting

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

NCT06958705Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

DrugsIbrutinib·Acalabrutinib·Orelabrutinib·Zanubrutinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-12-01

Recruiting

Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

NCT07435454Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2025-12-01

Recruiting

Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease

NCT07363538Complex Congenital Heart Disease

Central China Fuwai Hospital of Zhengzhou University

Not applicable

738

Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao

2025-12-01

Not yet open

Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

NCT07261592Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat, Chemotherapy

DrugEntinostat

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1/2

Nanjing

2025-12-01

Not yet open

Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer

NCT07238959Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm

Shanghai Changzheng Hospital

Observational

1,100

Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo

2025-12

Recruiting

The Physiological Effect of RCexp on Ventilation/Perfusion Distribution

NCT06919484Acute Respiratory Distress Syndrome, Mechanical Ventilation

Southeast University, China

Observational

Nanjing

2025-11-30

Not yet open

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

NCT06177522Pancreatic Cancer, Neoadjuvant Therapy

DrugsAlbumin-Bound Paclitaxel·Adebrelimab·Gemcitabine

Jinling Hospital, China

Phase 2

Nanjing

2025-11-30

Recruiting

Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 μg/Kgevery 8 Hours for Three Consecutive Days After Surgery.

NCT07514637Patients Who Undergo Pancreaticoduodenectomy

DrugAnrikefon

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2

Nanjing

2025-11-25

Not yet open

Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease

NCT07250685PD - Parkinson's Disease

Zhang Jianguo

Not applicable

Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou

2025-11-24

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing

2025-11-24

Recruiting

A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis

NCT07229742Active Lupus Nephritis

DrugSHR-2173

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 2

Nanjing

2025-11-22

Active, closed

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

NCT07162883Carcinoma, Non-Small-Cell Lung

DrugsKeytruda·Pembrolizumab

Qilu Pharmaceutical Co., Ltd.

Phase 3

146

Bengbu, Beijing, Chongqing, Lanzhou, Haikou, Zhengzhou, Changsha, Nanjing

2025-11-21

Not yet open

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

NCT06683131Acute Myocardial Infarction (AMI)

DrugTafolecimab

The Affiliated Hospital of Xuzhou Medical University

Phase 4

1,160

Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai

2025-11-20

Recruiting

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

NCT07343791DC-CIK Treatment, Regorafenib, Colorectal Cancer, Immune Combination Therapy

JIANG LONGWEI

Early Phase 1

Nanjing

2025-11-19

Recruiting

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

NCT07363460Lupus Nephritis (LN)

DrugsHSK39297 200mgQD·HSK39297 300mgQD

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

105

Nanjing

2025-11-18

Recruiting

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

NCT07095868Selected Types of Solid Tumor

Everest Medicines (Beijing) Co., Ltd.

Phase 1/2

Changsha, Nanjing, Shanghai

2025-11-17

Recruiting

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

NCT07161388Limited Stage Small-Cell Lung Cancer

AstraZeneca

Observational

200

Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing

2025-11-17

Recruiting

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer

DrugGKL-006

Beijing Gene Key Life Technology Co., Ltd

Phase 2

Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou

2025-11-14

Recruiting

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

NCT07361003Refractory Metastatic Colorectal Cancer

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3

464

Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou

2025-11-12

Recruiting

Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)

NCT07805967Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)

Second Affiliated Hospital of Soochow University

Observational

500

Changshu, Huai'an, Kunshan, Nanjing, Nantong, Suqian, Suzhou, Xuzhou

2025-11-12

Recruiting

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

NCT07228364Autosomal Dominant Polycystic Kidney Disease

DrugAZD1613

AstraZeneca

Phase 1

Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen

2025-11-10

Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101Ulcerative Colitis

DrugsZotemtegrast·Mirikizumab

Eli Lilly and Company

Phase 2

252

Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang

2025-11-10

Recruiting

A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

NCT07265921Advanced Solid Cancer

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

232

Beijing, Nanjing, Shanghai, Tianjin, Wuhan

2025-11-07

Active, closed

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

NCT07245953Chronic Hepatitis B

DrugsHT-101·HT-102

Suzhou HepaThera Biotech Co., Ltd.

Phase 2

Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang

2025-11-05

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

NCT07121413Idiopathic Pulmonary Fibrosis(IPF)

DrugSV001

Shanghai Synvida Biotechnology Co.,Ltd.

Phase 2

Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin

2025-11-04

By invitation

Consistency of Fluid Tolerance Evaluation Methods and Their Correlation With Clinical Outcomes in Patients With Shock

NCT07373717Shock

Southeast University, China

Observational

Nanjing

2025-11-02

Active, closed

Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis

NCT07396467Lung Cancer (Diagnosis), Pulmonary Fibrosis, Interstitial Lung Diseases

The First Affiliated Hospital with Nanjing Medical University

Observational

200

Nanjing

2025-11-01

Recruiting

AD-SVF Therapy for Refractory Endometrial Infertility

NCT07230600Endometrium; Atrophy, Intrauterine Synechiae

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 1

Nanjing

2025-11

Recruiting

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593Peripheral Arterial Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,205

Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin

2025-10-31

Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751Breast Neoplasms

DrugsEribulin·Pumitamig·Gemcitabine·Carboplatin

BioNTech SE

Phase 3

558

Changde, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing

2025-10-30

Active, closed

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109Respiratory Syncytial Virus Infections

DrugRSVPreF3 OA vaccine

GlaxoSmithKline

Phase 3

750

Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming

2025-10-29

Recruiting

Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis

NCT07263425Leptomeningeal Metastasis of HER2-positive Breast Cancer

DrugAdministration of Thiotepa

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-10-27

Recruiting

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

NCT07109986Systemic Lupus Erythematosus, Lupus Nephritis

Nanjing IASO Biotechnology Co., Ltd.

Phase 1

Nanjing

2025-10-27

Recruiting

Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

NCT06968806Aortic Dissection, Inflammation

DrugKetorolac

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3

1,346

Nanjing

2025-10-27

Recruiting

A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma

Prolium Bioscience, Inc

Phase 1/2

Beijing, Guangzhou, Henan, Nanchang, Nanjing, Pingxiang

2025-10-27

Recruiting

A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer

NCT07263386Gastric Adenocarcinoma

DrugSintilimab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

460

Nanjing

2025-10-23

Recruiting

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

NCT07219173Asthma

DrugBrenipatide

Eli Lilly and Company

Phase 2

531

Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai

2025-10-22

Recruiting

An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies

NCT07668453Biliary Tract Neoplasms

DrugsAlbumin-Bound Paclitaxel /nab-Paclitaxel·Adebrelimab·Gemcitabine

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-10-20

Recruiting

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

NCT07166263Gastric Cancer (GC), Colorectal Cancer

DrugNK510

Base Therapeutics (Shanghai) Co., Ltd.

Early Phase 1

Nanjing

2025-10-16

Recruiting

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

NCT07209761Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis

DrugsPretomanid·Bedaquiline·Linezolid·Moxifloxacin

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

532

Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu

2025-10-16

Recruiting

HD-tDCS for Adolescent Bipolar Depression Targeting S1

NCT07246044Adolescent, Bipolar Depression, tDCS, Primary Somatosensory Cortex

Jiangsu Province Nanjing Brain Hospital

Not applicable

100

Nanjing

2025-10-15

Recruiting

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

NCT07303465KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC)

DrugRNK08954

Ranok Therapeutics (Hangzhou) Co., Ltd.

Phase 2

Nanjing, Shanghai

2025-10-14

Recruiting

A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases

NCT07095075Relapsed/Refractory Autoimmune Diseases

Nanjing Legend Biotech Co.

Early Phase 1

Bengbu, Hefei, Nanjing, Suzhou, Wenzhou

2025-10-14

Recruiting

Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD

NCT07418177AMD - Age-Related Macular Degeneration

DrugsErlotinib·Prednisone

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2

Nanjing

2025-10-14

Recruiting

Sigh Ventilation in Cardiac Surgery

NCT07024420Postoperative Pulmonary Complications (PPCs), Cardiac Surgery in Adult Patient

Zhongda Hospital

Not applicable

686

Nanjing

2025-10-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913Mania, Bipolar Disorder

DrugKarXT

Bristol-Myers Squibb

Phase 3

424

Beijing, Guangzhou, Baoding, Shijiazhuang, Changsha, Nanjing, Xi'an, Chengdu

2025-10-08

Not yet open

Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP

NCT07200336Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugMepolizumab

Eye & ENT Hospital of Fudan University

Phase 4

360

Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing

2025-10-08

Active, closed

Electro-acupuncture for SCD With Depression

NCT07350226Subjective Cognitive Decline (SCD), Depression Disorder

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Not applicable

Nanjing

2025-10-01

Not yet open

A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.

NCT07156643Locally Advanced Soft Tissue Sarcoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-10-01

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Xiamen, Guangzhou, Huizhou, Shenzhen, Wuhan, Changsha, Nanjing, Wuxi

2025-10-01

Recruiting

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

NCT07185373Primary Central Nervous System Lymphoma

DrugsTeniposide·Orelabrutinib·Rituximab·Dexamethasone

Huashan Hospital

Phase 2/3

215

Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai

2025-10-01

Not yet open

Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia

NCT07075237Schizophrenia

DrugPaliperidone Palmitate

Jiangsu Province Nanjing Brain Hospital

Phase 4

120

Nanjing

2025-10

Recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762Urothelial Cancer

DrugsIza-bren·Gemcitabine·Cisplatin·Carboplatin

Bristol-Myers Squibb

Phase 2/3

470

Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong

2025-09-30

Not yet open

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

NCT07135141Severe Obesity

Beijing Friendship Hospital

Not applicable

256

Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai

2025-09-30

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Beijing, Chengdu, Guangzhou, Nanjing

2025-09-30

Recruiting

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

NCT07202884Urinary Incontinence,Stress

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,000

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing

2025-09-30

Active, closed

A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy

NCT07176702Metastatic PDAC, HER2-positive Status

DrugHLX22

Shanghai Zhongshan Hospital

Phase 2

Nanjing, Shanghai

2025-09-30

Not yet open

EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial

NCT07187284HCC - Hepatocellular Carcinoma

Zhongda Hospital

Phase 1/2

Nanjing

2025-09-30

Recruiting

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes

DrugMazdutide

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3

420

Changsha, Changzhou, Nanjing, Dalian, Shanghai

2025-09-27

Recruiting

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

100

Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou

2025-09-25

Recruiting

An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules

NCT07185035Pulmonary Nodules, Solitary, Pulmonary Nodules, Multiple

The First Affiliated Hospital with Nanjing Medical University

Early Phase 1

Nanjing

2025-09-20

Recruiting

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

DrugDelamanid

WestVac Biopharma Co., Ltd.

Phase 2

Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai

2025-09-19

Recruiting

JS207 Combination Therapy in Triple-negative Breast Cancer

NCT07045311Triple-negative Breast Cancer

Drugs9MW2821·JS207·Albumin paclitaxel

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing

2025-09-17

Recruiting

Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

NCT07163650Obesity, Weight Loss, Metabolic Surgery

DrugEfsubaglutide Alfa

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 4

Nanjing

2025-09-16

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471Osteoarthritis

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing

2025-09-15

Recruiting

Intent of Surgery for IPMN

NCT07216521Intraductal Papillary Mucinous Neoplasm

NYU Langone Health

Observational

2,000

Nanjing

2025-09-15

Recruiting

Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block

NCT07153263Pulmonary Nodules, Nerve Block

Nanjing First Hospital, Nanjing Medical University

Not applicable

Nanjing

2025-09-12

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan

2025-09-10

Recruiting

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07174908Non-Small Cell Lung Cancer

DrugsD-1553·IN10018

InxMed (Shanghai) Co., Ltd.

Phase 3

400

Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang

2025-09-10

Recruiting

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease

DrugRuxolitinib

Novartis Pharmaceuticals

Phase 4

Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing

2025-09-09

Active, closed

Impact of Intraoperative Blood Pressure Components on Postoperative AKI: A Phenotype-Stratified Analysis

NCT07156474Postoperative Acute Kidney Injury, Intraoperative Hypotension

Lanyue Zhu

Observational

44,504

Nanjing

2025-09-09

Recruiting

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

NCT07139873Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugsIdelalisib·Birelentinib·Bendamustine·Rituximab

Dizal Pharmaceuticals

Phase 3

250

Nanjing, Tianjin

2025-09-08

Recruiting

A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

NCT07099430Advanced Melanoma

DrugsLBL-024·Toripalimab

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

280

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan

2025-09-05

Recruiting

A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

NCT07082179NSCLC

DrugsCisplatin/Carboplatin·Iparomlimab and Tuvonralimab

Jiangsu Cancer Institute & Hospital

Phase 2

Nanjing

2025-09-04

Recruiting

QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

NCT07110064Advance Pancreatic Cancer

DrugLenvatinib

Du Juan

Phase 2

Nanjing

2025-09-03

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong

2025-09-02

Not yet open

Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules

NCT07135297Lung Cancer (Diagnosis)

Shanghai Chest Hospital

Not applicable

465

Beijing, Zhengzhou, Nanjing, Ningbo, Shanghai

2025-09-01

Not yet open

Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.

NCT07105956Alzheimer's Disease (AD)

Nanjing First Hospital, Nanjing Medical University

Observational

Nanjing

2025-09-01

Recruiting

Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer

NCT07718490Metastatic Colorectal Cancer

DrugAdebrelimab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-09-01

Active, closed

Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

NCT07300488HCC

DrugRegorafenib

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Phase 2/3

Nanjing

2025-09-01

Not yet open

RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China

NCT07075029Acute Respiratory Infections (ARIs)

Huashan Hospital

Observational

28,800

Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang

2025-09-01

Not yet open

Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial

NCT07050524Gastric Cancer Stage III

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-09-01

Not yet open

Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection

NCT06986512Rapid Detection, Pseudomonas Aeruginosa Infection

The First Affiliated Hospital with Nanjing Medical University

Observational

100

Nanjing

2025-09-01

Recruiting

Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions

NCT07093788PCI, Coronary Arterial Disease (CAD), Calcified Coronary Lesions

Nanjing First Hospital, Nanjing Medical University

Not applicable

Lianyungang, Nanjing, Yixing

2025-09-01

Recruiting

Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy

NCT07294859Nephrectomy, Renal Cell Cancer, AKI - Acute Kidney Injury

Jinling Hospital, China

Observational

285

Nanjing

2025-09-01

Recruiting

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

NCT07240194Large B-cell Lymphoma, TP53

DrugsGlofitamab·Obinutuzumab·Lenalidomide

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-09-01

Not yet open

Study on Proteomic and Microbiome Changes in Patients With Hepatic Encephalopathy (HE)

NCT07150195Cirrhoses, Liver, Hepatic Encephalopathy (HE)

The First Affiliated Hospital with Nanjing Medical University

Observational

Nanjing

2025-09

Not yet open

Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

NCT06925555EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-09

By invitation

Diagnostic Application of AI-ROSE in Severe Pneumonia

NCT07113951Severe Pneumonia, Bacterial Infections

The First Affiliated Hospital with Nanjing Medical University

Observational

100

Nanjing

2025-08-31

Not yet open

Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis

NCT07131150Idiopathic Pulmonary Fibrosis (IPF)

Ruijin Hospital

Phase 2

Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing

2025-08-31

Not yet open

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

NCT07113964Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

DrugsOlaparib·Lenvatinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-08-30

Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine

BeOne Medicines

Phase 3

351

Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang

2025-08-27

Recruiting

LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft

NCT07773051Arteriovenous Graft

Longhua Hospital

Not applicable

326

Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang

2025-08-25

Recruiting

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706Non-small Cell Lung Cancer (NSCLC)

DrugTaletrectinib

Nuvation Bio Inc.

Phase 3

180

Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang

2025-08-21

Not yet open

Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas

NCT07129499Colorectal Adenoma, High Risk, TCM

DrugShenbai

Jiangsu Famous Medical Technology Co., Ltd.

Not applicable

450

Nanjing

2025-08-15

Recruiting

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies

NCT07105735Autoimmune Diseases Refractory to Standard Therapies

DrugAllogeneic CAR-T

The First Affiliated Hospital with Nanjing Medical University

Phase 1

Nanjing

2025-08-15

Not yet open

Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas

NCT07123116Colorectal Adenoma, TCM, Low Risk

DrugShenbai

Jiangsu Famous Medical Technology Co., Ltd.

Not applicable

450

Nanjing

2025-08-15

Recruiting

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

NCT07125755Squamous Cell Cancer of Head and Neck (SCCHN)

DrugCisplatin

Sun Yat-sen University

Phase 3

386

Guangzhou, Guilin, Sanya, Changsha, Nanjing

2025-08-15

Recruiting

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

NCT07208981Marginal Zone Lymphoma(MZL)

DrugsOrelabrutinib·Bendamustine·Lenalidomide·Rituximab

The First Affiliated Hospital with Nanjing Medical University

Phase 2

169

Nanjing

2025-08-14

Recruiting

Clinical Performance Evaluation of a Diagnostic Ultrasound System

NCT07066449Echocardiography

GE Healthcare

Observational

Nanjing

2025-08-12

Not yet open

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

NCT07131501Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1

DrugsIparomlimab and Tuvonralimab·Lenvatinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2

Nanjing

2025-08-11

Recruiting

Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease

NCT07031531Premature Coronary Heart Disease

China National Center for Cardiovascular Diseases

Not applicable

4,900

Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou

2025-08-08

Recruiting

China Colorectal Cancer Screening Trial 1 (C-Cost1)

NCT07090291Colorectal Cancer, Advanced Adenoma

Zhejiang University

Not applicable

60,300

Guandong, Guangdong, Hebei, Nanjing, Shanghai, Sichuan, Zhejiang

2025-08-08

Active, closed

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

212

Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan

2025-08-07

Active, closed

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

NCT07081633Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 2

114

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing

2025-08-05

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)

Shanghai Henlius Biotech

Phase 2

Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing

2025-08-05

Recruiting

MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)

Suzhou Mednovo Yi Medical Technology Co., Ltd.

Phase 1

Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai

2025-08-04

Not yet open

Effect of Xuebijing InjecTion on Outcomes in Sepsis Patients Under Real-World Conditions（EXIT-SEP REAL）

NCT07069894Sepsis

Southeast University, China

Observational

5,400

Nanjing

2025-08-01

Recruiting

The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Observational

250

Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan

2025-08-01

Not yet open

A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

NCT07101627Lung Cancer

DrugHetrombopag

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2

149

Nanjing, Shanghai

2025-08-01

Recruiting

Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis

NCT07696351Deep Infiltrating Endometriosis (DIE), Infertility

DrugsGnRHa·Elacestrant

Li-jun Ding

Phase 4

120

Nanjing

2025-08-01

Recruiting

AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT

NCT07250347Gastric Cancer Stage, Gastric Cancer Patients Undergoing Gastrectomy

The First Affiliated Hospital with Nanjing Medical University

Observational

8,000

Nanjing

2025-08-01

Not yet open

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

NCT07113496Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL), Multiple Myeloma (MM), Plasmablastic Lymphoma

DrugAllogeneic CAR-T

The First Affiliated Hospital with Nanjing Medical University

Phase 1

Nanjing

2025-08

Recruiting

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

NCT07079475Non-Small Cell Lung Cancer

DrugsDZD6008·Sunvozertinib·Osimertinib

Dizal Pharmaceuticals

Phase 1/2

220

Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai

2025-07-30

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,211 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

725 of the 1,211 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 237 have not yet opened recruitment, 216 are active but closed to new participants, and 33 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjing), 1,211 studies
Phase	Studies	Recruiting	Share
Not applicable	275	161	22.7%
Phase 2	240	155	19.8%
Observational	224	139	18.5%
Phase 3	222	113	18.3%
Phase 1	76	51	6.3%
Phase 1/2	73	53	6%
Phase 4	48	24	4%
Early Phase 1	31	15	2.6%
Phase 2/3	22	14	1.8%

Most active sponsors

Lead sponsors with the most studies (Nanjing)
Lead sponsor	Studies	Recruiting
The First Affiliated Hospital with Nanjing Medical University	203	132
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	87	54
Nanjing First Hospital, Nanjing Medical University	72	44
Nanjing Medical University	30	15
The Second Hospital of Nanjing Medical University	30	19
AstraZeneca	27	17
Zhongda Hospital	27	14
Jinling Hospital, China	25	20
Novartis Pharmaceuticals	25	7
Southeast University, China	22	14

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.